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Abstract: In contrast to the well-established association between ultraviolet radiation (UVR) exposure
and skin cancers, the relationship between UVR and uveal malignant melanoma (UM) remains
controversial. To address this controversy, we evaluated the incidence rates of cutaneous malignancies
in the eyelids as a proxy for UVR exposure in the ocular region using a population-based cancer
registry. Overall, 74,053 cases of eyelid basal cell carcinoma (BCC) and 7890 cases of melanoma over a
26-year period (1982–2007) were analyzed. The incidence of eyelid basal cell carcinoma and uveal
melanoma remained stable, whereas other cutaneous areas demonstrated an increase in the rates.
A comparability test demonstrated that BCC incidence trends were significantly different between the
eyelid versus both chronically exposed (males p = 0.001; females p = 0.01) and intermittently exposed
skin (males and females, p = 0.0002), as well as the skin of the face (males p = 0.002; females p = 0.02).
Similarly, melanoma trends were significantly different between the UM group versus both chronically
exposed cutaneous melanoma (CM) (males p = 0.001; females p = 0.04) and intermittently exposed
CM (males p = 0.005), as well as facial skin CM (males and females p = 0.0002). The discrepancy of
cancer incidence between tumors in the peri-ocular region versus the rest of the body suggests that
the peri-ocular region might have a different or unique exposure pattern to ultraviolet radiation.
Keywords: ocular tumors; cutaneous melanoma; skin cancer; basal cell carcinoma; ultraviolet
radiation; uveal melanoma; eye exposure

1. Introduction
Uveal (intra-ocular) malignant melanoma is the most common primary intra-ocular malignancy,
and poses a significant risk of both vision loss and death, with up to 50% of patients dying of
their disease [1,2]. It is also the second most common location for malignant melanoma to develop,
after the skin [3,4]. Despite recent advances in treatment that often allow preservation of the eye
(epi-scleral plaque brachytherapy, proton beam radiotherapy, stereotactic radiotherapy, local resection,
and transpupillary thermotherapy) [5], there has been no improvement in survival outcomes [2,6].
This highlights the importance of understanding the underlying etiology of uveal malignant melanoma
(UM) in order to best direct primary prevention.
There is a well-established causal link between ultraviolet radiation (UVR) exposure and
both melanoma and non-melanoma skin cancers. [7–10] However, its role in the etiology of UM
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remains highly controversial [11–21]. In addition to sharing the same underlying malignant cell,
the neural-crest-derived melanocyte, there are significant similarities in the high-risk phenotype
for cutaneous malignancies and uveal melanoma, such as light-colored skin, the presence of nevi,
and light-colored eyes [18–24]. Furthermore, incidence rates of uveal melanoma have been shown
to decrease as skin pigmentation increases [25]. Other UV exposure factors such as latitude have
demonstrated inconsistent results, with a meta-analysis of five articles demonstrating no significant
association (OR = 1.08, 95% CI 0.67–1.74) [16]. Although the anterior segment (cornea, aqueous humor,
and lens) absorbs the majority of UVR striking the eye, photochemical damage can still occur in
the choroid [26]. Several studies assessing UM have not demonstrated UV signature mutations and
significant differences in mutations between CM, conjunctival melanoma, and UM [27–30]. However,
when controlling for intra-ocular location and its relation to UV exposure, UV signature genetic changes
have been found in posterior uveal melanomas [31]. In addition, less common non-classical mutations
found in uveal melanoma may be related to UV exposure [32]. The rising incidence of cutaneous
melanoma (CM) [11,12,33,34] that accompanied changes in social/behavioral patterns resulting in
intensifying sun exposure is in direct contrast to the incidence of UM that has been found to be
stable [11,12,35–37] or decreasing over the same period [38,39]. This difference in incidence rates is
one of the strongest criticisms of UVR as a causative factor in UM. Although these trends are indeed
divergent, meaningful conclusions based on this observation must account for anatomical locations
of lesions as well as their theoretically variable exposure patterns. Furthermore, characterizing the
type of UVR exposure is important, as it has been shown that its pattern is critical in the development
of CM whereby intermittent or recreational exposure, sunburns, childhood exposure, and chronic
occupational exposure have variable associations [14,23,40,41].
This study was therefore designed to evaluate the changes in UVR exposure to the ocular region
using BCC incidence as a proxy for UV exposure. Changes in incidence rates of basal cell carcinoma
(BCC) of the eyelid—a common tumor with a well-described association with UVR—are used as
a surrogate marker for changes in UVR exposure to the ocular region. These eyelid BCC rates are
then formally contrasted to the rates of UM in an attempt to evaluate previously held notions on the
association of UVR and UM. CM of the eyelid could not be used for this purpose, as its rarity would
preclude robust statistical analysis.
2. Results
A total of 81,943 tumors (74,053 BCC and 7890 malignant melanoma) were identified over a 26-year
period spanning 1 January 1982 to 31 December 2007. Of the BCC cases, 39,029 (52.7%) occurred in
males, and 35,024 (47.3%) in females. Of the malignant melanoma (CM and UM) cases, 3891 (49.3%)
occurred in males, and 3999 (50.7%) in females.
2.1. Age-Standardized Incidence Rates
Table 1 shows the average age-standardized incidence rates (ASIRs) of BCC and melanoma for
four anatomical groupings (eyelid, chronically exposed skin, face, and intermittently exposed skin).
For BCC, chronically UV exposed skin exhibited the largest average ASIR. Conversely, for melanoma,
intermittently UV exposed skin displayed the largest average ASIR. Specifically, for peri-ocular tumors,
the ASIR (per 100,000) for BCC of the eyelid was 6.72 ± 0.83 in males and 5.71 ± 0.70 in females, and for
UM, 0.49 ± 0.21 in males and 0.46 ± 0.19 in females.
2.2. Incidence Trends
Table 2 shows trends in tumor incidence based on the average annual percent change (AAPC)
derived from the underlying join point models of best fit. The incidence of BCC remained stable in
the eyelid over the study period in both males and females. By contrast, significant upward trends in
BCC incidence were observed in all other skin sites (chronically exposed skin, face, and intermittently
exposed skin). The AAPC could not be calculated for CM of the eyelid due to small sample size.
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Table 1. Average age-standardized incidence rates (ASIRs) for ophthalmic and non-ophthalmic basal
cell carcinoma and melanoma, 1982–2007.
Males
Anatomical Grouping

Females

Average
ASIR ± SE

n

n

Combined

Average
ASIR ± SE

n

Average
ASIR ± SE

Basal cell carcinoma
Eyelid

1867

6.72 ± 0.83

1844

5.71 ± 0.70

3711

6.13 ± 0.53

Chronically exposed skin

27,934

102.21 ± 3.29

24,819

77.52 ± 2.58

52,753

88.41 ± 2.03

Face

20,803

76.11 ± 2.84

20,296

63.56 ± 2.34

41,099

69.05 ± 1.80

Intermittently exposed skin

9228

29.91 ± 1.65

8361

24.15 ± 1.37

17,589

26.69 ± 1.05

Melanoma
Uvea

137

0.49 ± 0.21

144

0.46 ± 0.19

288

0.47 ± 0.14

Eyelid

12

0.04 ± 0.04

18

0.05 ± 0.04

30

0.04 ± 0.04

Chronically exposed skin

905

3.33 ± 0.60

573

1.71 ± 0.37

1478

2.42 ± 0.33

Face

464

1.81 ± 0.45

372

1.13 ± 0.30

836

1.42 ± 0.26

Intermittently exposed skin

2849

8.68 ± 0.86

3282

9.36 ± 0.86

6131

8.99 ± 0.61

Table 2. Incidence trends and the average annual percent change (AAPC) for ophthalmic and
non-ophthalmic basal cell carcinoma and melanoma, 1982–2007.
Males

Anatomical Grouping

Trend

Females

AAPC (95% CI)

Trend

AAPC (95% CI)

Basal cell carcinoma
Stable

−0.4 (−1.1 to 0.4)

Stable

0.6 (−0.1 to 1.2)

Chronically exposed skin

Increasing

1.8 * (0.9 to 2.8)

Increasing

1.7 * (1.1 to 2.4)

Face

Increasing

1.4 * (0.7 to 2.1)

Increasing

1.7 * (0.9 to 2.5)

Intermittently exposed skin

Increasing

6.3 * (5.1 to 7.6)

Increasing

6.4 * (5.2 to 7.7)

Stable

−0.9 (−2.9 to 1.2)

Eyelid

Melanoma
Uvea

Stable

Eyelid

§

−1.4 (−3.6 to 0.8)

§

Chronically exposed skin

Increasing

3.0 * (1.9 to 4.1)

Increasing

2.2 * (0.5 to 3.9)

Face

Increasing

2.4 * (1.0 to 3.8)

Stable

2.1 (−0.0 to 4.3)

Intermittently exposed skin

Increasing

3.2 * (1.9 to 4.5)

Increasing

2.0 * (0.6 to 3.3)

§ Unable to calculate due to low numbers; * Statistically significant difference.

A similar pattern of trends was observed for melanoma; the incidence of UM remained stable in
both males and females, while significant positive trends were observed for CM in chronically and
intermittently exposed skin. For CM in the facial skin, a statistically significant increase was seen in
males, and a borderline increasing trend in incidence was seen in females (2.1%, 95% CI 0.0–4.3).
2.3. Comparability Test
Table 3 shows the results of the test of parallelism between anatomical regions, comparing
peri-ocular/ocular (eyelid and uvea) and extra-ocular tumor incidence. BCC carcinoma change in
incidence was significantly different than all other locations. Tests of parallelism comparing incidence
trends for the eyelid versus other cutaneous regions revealed significantly different rates of change for
chronically exposed skin (Figure 1: males p = 0.001; females p = 0.01), the face (Figure 1: males p = 0.002
and females p = 0.02), and intermittently exposed skin (Figure 1: males p = 0.0002; females p = 0.0002).
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Table 3. Test of parallelism between anatomic groupings for basal cell carcinoma and melanoma,
1982–2007.
Test of Parallelism
Group 1

Result
Group 2

Males

Females

Basal cell carcinoma
Eyelid vs.

Chronically exposed skin vs.

Chronically exposed skin

* Not parallel (p = 0.001)

* Not parallel (p = 0.01)

Face

* Not parallel (p = 0.002)

* Not parallel (p = 0.02)

Intermittently exposed skin

* Not parallel (p = 0.0002)

* Not parallel (p = 0.0002)

Intermittently exposed skin

* Not parallel (p = 0.0002)

* Not parallel (p = 0.0002)

Chronically exposed skin

* Not parallel (p = 0.001)

* Not parallel (p = 0.04)

Face

* Not parallel (p = 0.002)

* Not parallel (p = 0.03)

Intermittently exposed skin

* Not parallel (p = 0.005)

Parallel (p = 0.06)

Intermittently exposed skin

Parallel (p = 0.81)

Parallel (p = 0.46)

Melanoma
Uvea vs.

Chronically exposed skin vs.

Inter-ophthalmic
Uveal malignant melanoma vs.

Eyelid basal cell carcinoma

Parallel (p = 0.08)

Parallel (p = 0.24)

* Statistically significant change over time.

Figure 1. Test of parallelism comparing incidence trends of ocular and cutaneous tumors using
registry data, 1982–2007. There is a statistically significant rising incidence in basal carcinoma and
cutaneous melanoma of the face, intermittently exposed skin, and chronically exposed skin when
compared to uveal melanoma or basal carcinoma of the eyelid. * Denotes non-parallel trend from
baseline (eyelid or uvea, p < 0.05). ASIR: age-standardized incidence rate; CE: chronically exposed;
IE: intermittently exposed.

For melanoma, tests of parallelism comparing incidence trends for UM versus CM found
significantly different rates of change. These changes were statistically significant for chronically
exposed skin (Figure 2: males p = 0.001; females p = 0.04), the face (Figure 2: males p = 0.0002 and
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females p = 0.0002), and intermittently exposed skin (Figure 2: males p = 0.005). As mentioned
previously, the rarity of CM of the eyelid precluded statistical analysis.

Figure 2. Test of parallelism comparing incidence trends between ocular tumors using registry data,
1982–2007. There is no statistically significant increase in the incidence of basal carcinoma of the eyelid
and uveal melanoma. § Denotes parallel trend (p < 0.05). ASIR: age-standardized incidence rate; BCC:
basal cell carcinoma; UMM: uveal malignant melanoma.

An additional test of parallelism was performed within the ocular groupings, comparing incidence
trends between UM and BCC of the eyelid. Incidence changes between UM and BCC of the eyelid
were not statistically different/occurred in parallel (Figure 2: males p = 0.08 and females p = 0.24).
3. Discussion
As sun exposure behaviors have changed, a strong association between the increasing incidence of
cutaneous malignancies and UVR has been documented [11,12,33,34]. However, for UM, the absence
of a similar increase in incidence over the same time period has been used as a principle argument
against its association with UVR [11,12,35–37]. The validity of this argument is based on the premise
that comparable increases in UVR exposure have occurred in the ocular region as in the rest of the body.
Our study, utilizing the well-established association between BCC of the skin and UVR, developed a
proxy variable that allowed for the assessment of changes in UVR exposure to the peri-ocular versus
extra-ocular regions.
UM is often considered as a single “intra-ocular” entity, yet it consists of three separate
topographical locations including the choroid, ciliary body, and iris. All topographies have the
neural-crest derived melanocyte within their cellular make-up, and thus carry its malignant potential.
Choroidal melanoma comprises the majority (80%) of cases, followed by the ciliary body, and then the
iris [11,12,42]. Due to its location behind the pigmented iris, the ciliary body likely receives significantly
less UVR exposure [31,43], and therefore is less likely to be associated with UVR (Figure 3). Accordingly,
its incidence would not be expected to vary with changing UVR exposure patterns. Unfortunately,
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ICD-O codes do not differentiate between the iris and ciliary body (C69.4). Thus, in an attempt to
directly evaluate the role of UVR on exposed intra-ocular structures, only cases of choroidal melanoma
were included in the analysis.

Figure 3. Sagittal schematic of the eye demonstrating ultraviolet exposure of iris and choroid,
with sparing of the ciliary body due to protection by the iris.

We report a stable trend in the incidence of eyelid BCC; however, there were upward trends for
non-eyelid BCC (chronically and intermittently exposed skin, and the face). This divergence suggests
that the ocular region displays a differential and unique exposure pattern to ultraviolet radiation that
was not subject to the same increases seen in other body sites.
In a similar manner, incidence rates of UM were compared to rates of CM in non-ocular sites.
Mirroring the eyelid BCC results, UM was found to have a stable incidence rate throughout the study
period, while CM incidence increased in chronically and intermittently exposed skin. Incidence rates
of eyelid BCC group were then directly compared to those of UM, revealing no statistical difference in
the change of incidence rates over the study period.
Prior research is consistent with the findings of this study, although there has been no previous
study quantitatively comparing peri-ocular malignancies to other anatomical locations [44–48]. A large
population-based study in the United States analyzed incidence rates for BCC and squamous cell
carcinoma during the years 1972–1973 and 1977–1978 and found that the incidence of both tumors
increased in nearly all sites, with the exception of the eyelid, which appeared to be decreasing [44].
A registry-based study in the Netherlands (1975–1988) reported a fluctuating pattern of BCC incidence
in the eyelids of females, while increases were observed for the face, neck, and scalp [45]. A large
population-based study in Finland (1953–1997) reported an average increase of eyelid BCC over its
entire period; however, incidence rates stabilized and began to decrease after 1983 [46]. Similarly,
a smaller registry study from Singapore (1968–1995) also reported an average increase in all eyelid
tumors (84% basal cell carcinoma) over the entire study period, but rates stabilized for males after 1978
and for females after 1983 [47]. Although not specific to BCC, a long-term registry-study in Sweden
(1960–2004) found evidence of another UVR-implicated tumor—squamous cell carcinoma—increasing
in all skin sites except the eyelid [48].
Although no formal statistical comparisons between UM and CM trends have been performed,
several reports have suggested a difference [11,12], consistent with the findings of this study. A large
population-based study from the United States (1974–1998) reported a stable annual percent change of
UM incidence, while the incidence of CM increased significantly for both chronically exposed skin (face
and ears, scalp and neck) and intermittently exposed skin (trunk and limbs) [11]. Similarly, a registry
study from Denmark (1943–1997) reported a stable trend in the incidence of UM, with an increasing
rate of CM in all skin sites, including the skin of the face, neck, and scalp [12].
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Independent of cancer incidence studies, the notion that the ocular region displays a unique
exposure pattern is furthered by a series of manikin, in vivo, and computational UVR studies [49–54].
Several investigators have employed manikins equipped with solar dosimeters localized across
anatomical regions to quantify UVR doses, finding that the ocular region displayed relatively lower
exposures compared to other parts of the face [49,50]. Using similar methods, others have demonstrated
substantial variability of ocular UVR exposure depending on the use of hats and eyewear and
environmental surface reflectivity [51,52]. Another study used computational methods to model
UVR exposure at higher resolutions, revealing the importance of reflective properties intrinsic to the
anatomy of the peri-ocular structures, calling into question prior dosimetry studies [53]. A review
article summarized that the ocular region is different from the skin in other areas secondary to an
increased component of reflected and scattered light, peak exposure varying due to the primary role
of incident light, the protective effects of the geometry of the face, and back reflection from eye and
sunglasses [54]. Although not affecting the eyelid, research has demonstrated that no UV light can pass
through the lens after the age of 20 [26]. Taken together, these exposure studies suggest that ocular
UVR exposure is unique and affected by many factors [55].
The strengths of this study included the use of high-quality registry data that covers a large
population, and the novel approach of using eyelid BCC—the most common eyelid malignancy in
Caucasian populations [56]—as a surrogate marker for UVR exposure to the ocular region. Although
unlikely to bias our analyses, one limitation of our study was the exclusion of registry data classified
topographically as “skin, not otherwise specified” and “overlapping lesion of the skin”; 242 cases of
CM and 2343 cases of BCC were coded as such, and would have amounted to only 3.0% and 3.1% of the
total number of cases, respectively. Another limitation is the absence of other relevant intra-ocular and
ocular-adnexal tumors in our study, namely malignant melanoma of the eyelid, conjunctiva, and iris;
these tumors were too rare to be subject to analysis, or the data were unavailable.
4. Materials and Methods
Research adhered to the tenets of the Declaration of Helsinki. Institutional Review Board approval
was obtained.
4.1. The Alberta Cancer Registry
Alberta is a province in Western Canada with a population of 3.7 million [57]. It has a universal
government-payer-based health care system and provincial cancer agency, providing care for all
residents of the province. The Alberta Cancer Registry has been awarded gold certification from
the North American Association of Central Cancer Registries for their 2006 incidence data based on
completeness, timely reporting, and other measures of data quality [58].
4.2. Data Selection and Age Standardization
Cancer incidence data were collected over a 26-year period (1982–2007) for cutaneous BCC and
cutaneous and uveal melanoma. Topographic areas were categorized to assess our hypothesis and
acknowledge and allow comparisons with prior research differentiating incidence rates of various
anatomical regions and their association with UV exposure. The following categories were retrieved
(Table 4): uvea (choroid), eyelid, chronically exposed skin (lip, ear, scalp, neck, face including nose),
unspecified parts of the face (not eyelid, lip, ear, scalp, neck), and intermittently exposed skin (trunk,
limbs). Only malignant neoplasms stated or presumed to be primary (behavior code 3) were included
(Table 3). UM is often considered as a single “intra-ocular” entity, yet it consists of three separate
topographical locations, including the choroid, ciliary body, and iris. The age-standardized incidence
rate (ASIR) was calculated separately for males and females, using the direct method with the United
States year 2000 standard population [59]. Annual Alberta population figures by age and sex were
obtained from the provincial government ministry of health. Non-Alberta residents were excluded
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from the dataset. Ethics approval was obtained from the Alberta Cancer Research Ethics Committee,
and the approval file was received.
Table 4. Topographical and morphological tumor groups for data retrieval, using the International
Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) histologic criteria.
Name

ICD-O Code

ICD-O Category

ICD-O Description

Topographical group criteria
Uvea

C69.3

Eye and adnexa

Choroid

Eyelid

C44.1

Skin

Eyelid

Chronically
exposed skin

C44.0, C44.2–C44.4

Skin

Skin of lip NOS, external ear, skin of other and
unspecified parts of the face, skin of scalp and neck

Face

C44.3

Skin

Skin of other and unspecified parts of the face

Skin

Skin of trunk, skin of upper limb and shoulder, skin of
lower limb and hip

Intermittently
exposed skin

C44.5–C44.7

Morphological tumor criteria

Basal cell
carcinoma

Malignant
melanoma

8090/3-8094/3, 8097/3,
8098/3

8720/3–8723/3, 8730/3,
8740/3–8746/3, 8761/3,
8770/3–8774/3,8780/3

Basal cell
neoplasms

Basal cell carcinoma, NOS; multifocal superficial basal
cell carcinoma; infiltrating basal cell carcinoma, NOS;
basal cell carcinoma, fibroepithelial; basosquamous
carcinoma; basal cell carcinoma, nodular; adenoid basal
cell carcinoma

Nevi and
melanomas

Malignant melanoma, NOS; nodular melanoma; balloon
cell melanoma; malignant melanoma, regressing;
amelanotic melanoma; malignant melanoma in
junctional nevus; malignant melanoma in precancerous
melanosis; lentigo maligna melanoma; superficial
spreading melanoma; acral lentiginous melanoma,
malignant; desmoplastic melanoma, malignant; mucosal
lentiginous melanoma; malignant melanoma in giant
pigmented nevus; mixed epithelioid and spindle cell
melanoma; epithelioid cell melanoma; spindle cell
melanoma, NOS; spindle cell melanoma, type A; spindle
cell melanoma, type B; blue nevus, malignant

Only choroidal melanomas were included in this study.

4.3. Joinpoint and the Comparability Test for Differences between Groups
Statistical analysis was performed with the Joinpoint Regression Program (National Cancer
Institute, Version 3.4.3) [60,61]. Briefly, for each tumor grouping’s log-linear model, an average annual
percent change (AAPC) in incidence was calculated for the entire study period [62]. AAPCs are a
weighted average of the final model’s individual trend segments, with a 95% confidence interval based
on a normal distribution that shows if the average trend is significant (increasing or decreasing) or
non-significant from zero (stable). A comparability test known as the test of parallelism [63] was
performed in Joinpoint to contrast incidence trend data between different anatomical groupings.
The significance level was set at p < 0.05.
5. Conclusions
The controversial association between UVR and UM has not yet been resolved. A primary
argument against this association is the observation that while CM time trends in incidence have risen
with increasing UV exposure in the past decades, UM rates have remained stable. This argument
assumes that changes in UVR exposure patterns of the ocular region are similar to those of the cutaneous
regions that have driven the increasing incidence rates. The results of our study refute this premise
by demonstrating that the ocular region has not been subject to an increase in UVR exposure with
changing sun behavior patterns.
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